… the subsequent clinical trials combining inhibitors of both MEK and mutant BRAF … inhibitor
monotherapy. In this review, we discuss existing clinical trial data on BRAF and MEK inhibitors …

… There is early clinical evidence that the combination of BRAF and MEK inhibitors shows
clinical activity in BRAF V600-mutant melanoma with a lower incidence of rash and BRAF-…

… MEK inhibitors are classed into ATP competitive and ATP non-competitive agents. Most of
the known MEK inhibitors fall into the latter category, and hence are not directly competing for …

… (MAPK) pathway (BRAF inhibitors and MEK inhibitors) and T-… of cases (BRAF and MEK
inhibitors). This review discusses … , and the use of BRAF and MEK inhibitors in combination. Both …

… In this review we discuss the latest evidence on the treatment of BRAF-mutated NSCLC,
including tumor biology, targeted treatment with BRAF and MEK inhibitors, therapeutic …

… There is evidence of anticancer activity of single-agent BRAF … , we summarize MEK inhibitors
in clinical development and offer recommendations for future research on MEK inhibitors. …

… therapy targeting BRAF and MEK, a … MEK inhibitor combinations have been approved for
use in various cancers by the US FDA. We review the clinical data for various BRAF plus MEK …

… as a mechanism for MEK inhibitor resistance in cells with … the addition of a RAF inhibitor
to a MEK inhibitor may delay or … Consistent with these results, new evidence suggests that …

… in models of BRAF or MEK inhibitor resistance, we generated … the BRAF inhibitor PLX4032
or the MEK inhibitor GSK1120212, … targeting MEK, especially in light of evidence suggesting …

… clinical properties of this new generation of ALK inhibitors under development in the clinic. …
in the group pretreated with an ALK inhibitor, ALK inhibitor-naive patients and the overall …